Therapeutic Potential of AntagomiR-23b for Treating Myotonic Dystrophy
Myotonic dystrophy type 1 (DM1) is a chronically debilitating, rare genetic disease that originates from an expansion of a noncoding CTG repeat in the dystrophia myotonica protein kinase (DMPK) gene. The expansion becomes pathogenic when DMPK transcripts contain 50 or more repetitions due to the seq...
Main Authors: | Estefanía Cerro-Herreros, Irene González-Martínez, Nerea Moreno-Cervera, Sarah Overby, Manuel Pérez-Alonso, Beatriz Llamusí, Rubén Artero |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-09-01
|
Series: | Molecular Therapy: Nucleic Acids |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2162253120302109 |
Similar Items
-
Preclinical characterization of antagomiR-218 as a potential treatment for myotonic dystrophy
by: Estefanía Cerro-Herreros, et al.
Published: (2021-12-01) -
Delivery of AntagomiR-7 through polymer nanoparticles for assisting B Cell to alleviate systemic lupus erythematosus
by: Hui Guo, et al.
Published: (2023-04-01) -
BlockmiR AONs as Site-Specific Therapeutic MBNL Modulation in Myotonic Dystrophy 2D and 3D Muscle Cells and HSA<sup>LR</sup> Mice
by: Sarah J. Overby, et al.
Published: (2023-03-01) -
Proof of concept of peptide-linked blockmiR-induced MBNL functional rescue in myotonic dystrophy type 1 mouse model
by: Sarah J. Overby, et al.
Published: (2022-03-01) -
Calcitriol increases MBNL1 expression and alleviates myotonic dystrophy phenotypes in HSALR mouse models
by: Kun Huang, et al.
Published: (2022-12-01)